BJH - volume 11, issue Abstract Book BHS, february 2020
S. Servais MD, PhD, F. Baron MD, PhD, C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD
BJH - volume 7, issue 6, december 2016
S. Servais MD, PhD, C. Grégoire MD, F. Baron MD, PhD, E. Willems MD, PhD, A. Briquet PhD, E. Baudoux MD, O. Delloye PhD, O. Giet PhD, C. Lechanteur PhD, Y. Beguin MD, PhD
Steroid-refractory acute graft-versus-host disease is a severe complication after allogeneic stem cell transplantation. So far, its treatment remains very challenging since the current therapies do not offer significant benefits. Among the most recent approaches, multipotent mesenchymal stromal cell-based therapy has attracted great interest over the past decade. Here, we briefly reviewed the current knowledges about the immunomodulatory properties of multipotent mesenchymal stromal cells as well as results of preclinical and clinical studies having assessed their efficacy to modulate steroid-refractory acute graft-versus-host disease.
(BELG J HEMATOL 2016;7(6):229–35)
Read moreBJH - volume 7, issue Abstract Book BHS, january 2016
C. Grégoire MD, Y. Beguin MD, PhD, M. Hannon , S. Dubois , B. Baudoux , A. Briquet PhD, C. Lechanteur PhD, G. Ehx , F. Baron MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
M. Binsfeld , Y. Beguin MD, PhD, L. Belle , E. Otjacques , M. Hannon , A. Briquet PhD, P. Drion , B. Bogen , F. Baron MD, PhD, J. Caers MD, PhD
BJH - 2013, issue BHS Abstractbook, january 2013
L. Belle , M. Binsfeld , M. Hannon , J. Caers MD, PhD, A. Briquet PhD, M. Menten , Y. Beguin MD, PhD, S. Humblet , F. Baron MD, PhD
BJH - 2013, issue BHS Abstractbook, january 2013
A. Briquet PhD, A. Halleux , C. Lechanteur PhD, Y. Beguin MD, PhD
Top
